SecSonar.com

ADMA Biologics, Inc. (ADMA)

ADMA Biologics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

ADMA Biologics, Inc. (ADMA) is a Biotechnology company based in US with a market capitalization of $1.9B. Revenue grew 19.6% year-over-year and the company generated $27.8M in free cash flow. This page tracks ADMA's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 685 employees · IPO Oct 17, 2013

Valuation

Valuation & price

$8.50 · as of May 15, 2026 · -58.3% vs 52w high

14.2

P/E ratio

Latest-FY diluted EPS

3.96

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$20.11$13.93$7.76Jul 25Dec 25Jul 26Jul 7, 25$17.88Jul 9, 25$18.34Jul 11, 25$18.51Jul 15, 25$17.98Jul 17, 25$17.59Jul 21, 25$17.13Jul 23, 25$17.20Jul 25, 25$18.01Jul 29, 25$18.26Jul 31, 25$18.70Aug 4, 25$19.91Aug 6, 25$18.54Aug 11, 25$16.38Aug 13, 25$17.20Aug 15, 25$16.99Aug 19, 25$17.44Aug 21, 25$17.10Aug 25, 25$17.01Aug 27, 25$17.25Aug 29, 25$17.26Sep 3, 25$16.90Sep 5, 25$16.87Sep 9, 25$16.39Sep 11, 25$16.11Sep 16, 25$15.69Sep 18, 25$16.16Sep 22, 25$16.03Sep 24, 25$15.66Sep 26, 25$15.61Sep 30, 25$14.66Oct 2, 25$14.53Oct 6, 25$14.07Oct 8, 25$14.62Oct 10, 25$14.54Oct 14, 25$14.95Oct 16, 25$14.56Oct 21, 25$14.72Oct 23, 25$15.25Oct 27, 25$15.60Oct 29, 25$15.53Oct 31, 25$15.48Nov 4, 25$14.63Nov 6, 25$14.03Nov 10, 25$14.71Nov 12, 25$16.46Nov 14, 25$15.56Nov 18, 25$15.69Nov 20, 25$16.36Nov 25, 25$19.21Nov 28, 25$19.18Dec 2, 25$19.25Dec 4, 25$20.11Dec 8, 25$19.39Dec 10, 25$19.98Dec 12, 25$19.78Dec 16, 25$19.17Dec 18, 25$18.81Dec 22, 25$19.88Dec 24, 25$19.54Dec 29, 25$19.11Jan 2, 26$17.88Jan 6, 26$18.34Jan 8, 26$18.07Jan 12, 26$17.93Jan 14, 26$18.28Jan 16, 26$17.31Jan 21, 26$17.36Jan 23, 26$16.73Jan 27, 26$16.58Jan 29, 26$17.01Feb 2, 26$17.50Feb 4, 26$16.49Feb 9, 26$16.37Feb 11, 26$16.28Feb 13, 26$16.09Feb 18, 26$15.99Feb 20, 26$16.10Feb 24, 26$15.52Feb 26, 26$15.18Mar 2, 26$16.58Mar 4, 26$16.54Mar 6, 26$15.39Mar 10, 26$15.83Mar 12, 26$14.99Mar 17, 26$16.15Mar 19, 26$15.02Mar 23, 26$13.59Mar 25, 26$9.63Mar 27, 26$9.25Mar 31, 26$9.01Apr 2, 26$9.19Apr 7, 26$9.26Apr 9, 26$9.94Apr 13, 26$10.38Apr 15, 26$10.65Apr 17, 26$11.01Apr 22, 26$10.95Apr 24, 26$11.26Apr 28, 26$10.90Apr 30, 26$10.25May 4, 26$10.31May 6, 26$10.08May 8, 26$8.17May 12, 26$8.41May 14, 26$8.50May 18, 26$8.38May 20, 26$8.56May 22, 26$8.24May 28, 26$7.93Jun 1, 26$7.90Jun 3, 26$7.76Jun 5, 26$7.97Jun 9, 26$8.12Jun 11, 26$8.32Jun 15, 26$8.50Jun 17, 26$8.42Jun 22, 26$8.57Jun 24, 26$8.70Jun 26, 26$8.75Jul 2, 26$8.95
$7.6052-week range$20.38
Loading valuation history…

Fundamentals

Key fundamentals

$1.9B

Market cap

19.6%

Revenue growth (YoY)

57.4%

Gross margin

$27.8M

Free cash flow (USD)

-$7.7M

Net debt

Net cash position

2.2%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$10.7MFY 2017$22.8MFY 2018$17.0MFY 2019$29.3MFY 2020$42.2MFY 2021$80.9MFY 2022$154.1MFY 2023$258.2MFY 2024$426.5MFY 2025$510.2M
$10.7M$510.2M

Free cash flow by year

2016 → 2025

FY 2016$-18.3MFY 2017$-39.9MFY 2018$-64.8MFY 2019$-80.0MFY 2020$-114.7MFY 2021$-125.9MFY 2022$-73.4MFY 2023$3.8MFY 2024$110.1MFY 2025$27.8M
-$18.3M$27.8M

Gross margin by year

2021 → 2025

FY 20211.4%FY 202222.9%FY 202334.4%FY 202451.5%FY 202557.4%
1.4%57.4%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 6, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventAnnual Meeting ResultsJun 2, 2026Filing
  • 8-K eventEarnings ReleaseMay 6, 2026Filing
  • Quarterly report10-Q FiledMay 6, 2026Filing
  • 8-K eventFDA ApprovalMay 4, 2026Filing

Questions

Frequently asked questions

What is ADMA Biologics, Inc.'s market cap?

ADMA Biologics, Inc. (ADMA) has a market capitalization of $1.9B.

What is ADMA's P/E ratio?

ADMA trades at a price-to-earnings ratio of 14.2, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

What is ADMA's price-to-book (P/B) ratio?

ADMA trades at 3.96 times book value per share.

Are insiders buying ADMA stock?

SEC Form 4 filings show no open-market insider buys at ADMA Biologics, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

SRPT

Sarepta Therapeutics, Inc.

$1.9B

ABCL

AbCellera Biologics Inc.

$1.9B

GLPG

Galapagos N.V.

$1.9B

BCRX

BioCryst Pharmaceuticals, Inc.

$1.9B

AAPG

Ascentage Pharma Group International

$1.9B

ZYME

Zymeworks Inc.

$1.9B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.